Chris Paradise

Chris Paradise, PhD, serves as Vice President of Research and Development at Rion, Inc., a clinical-stage biotechnology company headquartered in Rochester, MN. Rion’s flagship therapeutic, PEP, leverages the regenerative capacity of platelet-derived extracellular vesicles to provide cell-free regenerative therapies.

Chris has been involved in the translation of Rion’s extracellular vesicle therapeutic from its origins within academia to a clinical-stage Drug Product. This work has involved product and process characterization, analytical development, preclinical evaluation, and buildout of a robust CMC section to support IND submissions.

Chris received a Ph.D. in Biomedical Sciences from the Mayo Clinic Graduate School of Biomedical Sciences within the Center for Regenerative Medicine. He has contributed to over 30 publications within the field of Regenerative Medicine and remains active in the academic community. In addition to focused efforts on the development of PEP Drug Product, Rion’s Research and Development group maintains active collaborations with academic institutions dedicated to the advancement of novel regenerative technologies.